Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for co…
The Fight Illicit Pill Presses Act amends the Controlled Substances Act to require persons who manufacture, distribute, deliver, sell, import, export, broker, or trade tableting machines, encapsulating machines, or certain 'critical parts' (upper punch, lower punch, die) to permanently affix and record serial numbers on those machines and parts. Regulated persons must report transactions in these machines and include the serial numbers in reports to the Attorney General.
Degree of concern about regulatory burden: conservatives emphasize federal overreach and costs while liberals emphasize enforcement effectiveness and equitable implementation.
Relative to its intended legislative type, this bill effects a substantive change to the Controlled Substances Act by creating new definitional coverage, recordkeeping/reporting obligations, and prohibited acts related to tableting and encapsulating machines and certain parts.
The Fight Illicit Pill Presses Act amends the Controlled Substances Act to require persons who manufacture, distribute, deliver, sell, import, export, broker, or trade tableting machines, encapsulating machines, or certain 'critical parts' (upper punch, lower punch, die) to permanently affix and record serial numbers on those machines and parts.
Regulated persons must report transactions in these machines and include the serial numbers in reports to the Attorney General.
The Attorney General must promulgate regulations within 180 days including guidance for machines and parts manufactured before enactment; the serial-number requirement applies to machines and parts handled after the effective date of those regulations.
By content and structure the bill is a modest, targeted amendment to existing drug‑control statute with phased compliance and clear implementing authority, characteristics that historically make passage more plausible than sweeping or highly partisan measures. The absence of large new spending, its operational focus, and built‑in phasing increase its chances. Remaining obstacles include industry opposition, regulatory implementation questions, and any Senate procedural hurdles.
Relative to its intended legislative type, this bill effects a substantive change to the Controlled Substances Act by creating new definitional coverage, recordkeeping/reporting obligations, and prohibited acts related to tableting and encapsulating machines and certain parts. The drafting is precise in statutory placement and definitions and provides a clear regulatory lead and timeline, but it defers several operational details to Attorney General rulemaking and contains no fiscal or resourcing statements.
Degree of concern about regulatory burden: conservatives emphasize federal overreach and costs while liberals emphasize enforcement effectiveness and equitable implementation.
These are examples from the analysis, not a ranked list of the most-affected groups.
Degree of concern about regulatory burden: conservatives emphasize federal overreach and costs while liberals emphasize enforcement effectiveness and equitable implementation.
A mainstream liberal would likely view this bill as a targeted, pragmatic law-enforcement and public-health measure to disrupt illicit pill production (notably fentanyl-laced counterfeit pills).
They would see serial-numbering and recordkeeping as a useful traceability tool that can help investigators and prosecutors follow the supply chain.
However, they may worry about enforcement priorities, the potential for disparate impacts on small or minority-owned businesses, and ensuring rules are not used to over-criminalize low-level actors.
A centrist or moderate would typically see this bill as a reasonable, narrowly scoped measure to hamper the illicit production of counterfeit opioid pills while leaving legitimate manufacturing legal.
They would support the idea of traceability as a proportionate regulatory response but want clarity on implementation costs, timelines, and enforcement mechanisms.
They would emphasize the need for clear regulations from the Attorney General, proportionate penalties, and oversight to ensure the rulemaking is practical and minimizes unintended burdens on lawful commerce.
A mainstream conservative is likely to support the bill’s objective of combating illegal fentanyl production and view serial-numbering as a useful law-enforcement tool, but will be attentive to regulatory burden, federal overreach, and impacts on lawful industry and trade.
They may be uncomfortable with fast or expansive rulemaking authority granted to the Attorney General and will press for limits on compliance costs, intrusiveness, and liability for legitimate businesses.
Conservatives may favor sharper targeting of criminal actors and ensuring the law does not create a de facto licensing regime or undue barriers to commerce.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
By content and structure the bill is a modest, targeted amendment to existing drug‑control statute with phased compliance and clear implementing authority, characteristics that historically make passage more plausible than sweeping or highly partisan measures. The absence of large new spending, its operational focus, and built‑in phasing increase its chances. Remaining obstacles include industry opposition, regulatory implementation questions, and any Senate procedural hurdles.
The bill has not accumulated any surfaced votes yet.
Degree of concern about regulatory burden: conservatives emphasize federal overreach and costs while liberals emphasize enforcement effecti…
By content and structure the bill is a modest, targeted amendment to existing drug‑control statute with phased compliance and clear impleme…
Relative to its intended legislative type, this bill effects a substantive change to the Controlled Substances Act by creating new definitional coverage, recordkeeping/reporting obligations, and prohibited acts related…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.